Biotech company, Opthea
(ASX:OPT) has announced that recruitment into the company's ongoing Phase 2b trial of (OPT-302) for wet age related macular degeneration is complete ahead of schedule.
As a result of the early completion the reporting of primary data from the study will now be brought forward and is expected in the fourth quarter of calendar year 2019.
The phase 2b trial is a double-masked, randomized, controlled study to investigate with the addition of Opthea's therapy offer a 6 month period improves clinical outcomes.
The trial will assess 351 patients at 113 clinical sites in the US, Europe and Israel.
